FDA - Spark Newswire

3 minute read

Altamira Therapeutics’ SemaPhore Delivery Platform Shows Significant Synergis-tic Effects Of ZBTB46 mRNA With PD1 Immunotherapy In Control Of Tumor Growth In Animal Model

Today, 9:49 PM

Preprint of results from animal study shows restriction of tumor growth in mice treated with ZBTB46 mRNA nanoparticles based on Altamira's SemaPhore™ delivery technology Nanoparticle treatment combined with

CYTO

1 minute read

Republicans Seek Documents, Schedule Hearing Related To FDA’s Response To Baby-Formula Shortage

By Vandana Singh

Today, 9:49 PM

House Republicans are reportedly speeding up their scrutiny of the FDA and the White House's handling of the baby formula shortage last year.

ABT

2 minute read

Despite Failed Phase 3 Study, FDA Staff Says Biogen’s ALS Drug May Have Clinical Benefit

By Vandana Singh

Today, 9:49 PM

FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will virtually meet on Wednesday, March 22, to discuss Biogen Inc’s (NASDAQ:BIIB) ALS…

BIIB

1 minute read

Sanofi Announced Earlier: Dupixent Approved By European Commission As First And Only Targeted Medicine For Children As Young As Six Months Old With Severe Atopic Dermatitis

By Charles Gross

Today, 9:49 PM

Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease severity compared to placebo

SNY

3 minute read

Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder

By Lara Goldstein

Today, 9:49 PM

Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions.

FLHLF

1 minute read

Silo Pharma Announces Results From IND-Enabling Study Of SP-26 For Fibromyalgia; Shares Move Higher

By Happy Mohamed

Today, 9:49 PM

Silo Pharma, Inc. (NASDAQ:SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has achieved

SILO

1 minute read

Roivant Announces Phase 3 Trial Of VTAMA Achieved Primary Endpoint And All Secondary Endpoints

By Bill Haddad

Today, 9:49 PM

46.4% of subjects receiving VTAMA cream, 1% achieved the primary endpoint of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM) response of clear (0) or almost clear (1) with at

ROIV